There are currently 2707 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Medical Residents Learning Weight Management Counseling Skills
NCT06529666
Recruiting
The goal of this study is to addresses the lack of weight management training physicians receive during their residency training. The main questions it aims to answer are: * How affective is the MRWeight curriculum at increasing medical residents weight management counseling (WMC) skills. * Evaluate residents' adoption of WMC skills in encounters with their patients * what would be the best way to get residents to adopt the WMC skills Residents in the comparison group will receive a course on o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: Boston University, Boston, Massachusetts
Conditions: Weight Management, Patient Counseling, Video Communication Asssessments
Register for Updates
TRAQinform Assessment of Immunotherapy Response
NCT05819255
Recruiting
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma
Register for Updates
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580
Recruiting
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
NCT04102371
Recruiting
The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.
Gender:
ALL
Ages:
Between 2 months and 17 years
Trial Updated:
07/25/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Shock, Septic
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072
Recruiting
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Massachusetts General Hospital Hematology Oncology, Boston, Massachusetts
Conditions: Metastatic Uveal Melanoma
Register for Updates
Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis
NCT06194123
Recruiting
The objective of this study is to evaluate how well the study product, Crest Daily Whitening Serum, alleviates Xerostomia and perceived halitosis over 1 week of use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Tufts University School of Dental Medicine, Boston, Massachusetts
Conditions: Xerostomia, Halitosis
Register for Updates
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02227251
Recruiting
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
Recruiting
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer
Register for Updates
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
NCT06202183
Recruiting
This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorectal cancer. The names of the study groups involved in this study are: * Exercise * Waitlist Control
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
Register for Updates
Virtual Reality Intervention for Fear of Heights
NCT06468878
Recruiting
Exposure-based cognitive behavior therapy is an efficacious treatment for acrophobia (fear of heights) and has been delivered effectively in a virtual reality (VR) environment. The present study is designed to evaluate the effects of liked, non-lyrical background music on the efficacy of a brief VR exposure intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Boston University, Boston, Massachusetts
Conditions: Acrophobia
Register for Updates